

Ref: Syn/CS/SE/RPT/2020-21/June/20

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India

T+91 80 6775 8000 F+91 80 6775 8808

CIN: L85110KA1993PLC01493

www.syngeneintl.com

Scrip Code: 539268	Scrip Symbol: SYNGENE
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051
Corporate Relationship Department	Corporate Communication Department
BSE Limited	National Stock Exchange of India Limited
The Manager,	The Manager,
То,	To,

Dear Sir/Madam,

June 10, 2020

#### **Subject: Submission of Disclosure on Related Parties Transactions**

Pursuant to Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions on Consolidated basis for the half-year ended March 31, 2020, drawn in accordance with the applicable Accounting Standards.

The above-mentioned disclosure will also be available on website of the Company <a href="https://www.syngeneintl.com">www.syngeneintl.com</a>.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED** 

Priyadarshini Mahapatra

**Company Secretary and Compliance Officer** 



# DISCLOSURE OF RELATED PARTY TRANSACTIONS – ON CONSOLIDATED BASIS

In pursuance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

## A. List of key management personnel

SI No	Name of the related party	Relationship	
(a)	Kiran Mazumdar Shaw	Chairperson (w.e.f. 1 April 2020)	
	Kiran Mazumdar Shaw	Chairperson and Managing Director	
		(till 31 March 2020)	
(b)	John Shaw	Non-executive director	
(c)	Jonathan Hunt	Managing Director and Chief Executive Officer	
		(w.e.f. 1 April 2020)	
	Jonathan Hunt	Director and Chief Executive Officer	
		(till 31 March 2020)	
(d)	Catherine Rosenberg	Non-executive director	
(e)	Bala S. Manian	Independent director	
(f)	Paul Blackburn	Independent director	
(g)	Vijay Kuchroo	Independent director	
(h)	Vinita Bali	Independent director	
(i)	Sharmila Abhay Karve	Independent director (w.e.f. 1 August 2019)	
(j)	Carl Decicco	Independent director (w.e.f. 1 October 2019)	
(k)	M.B. Chinappa	Chief Financial officer (till 17 December 2019)	
(1)	Sibaji Biswas	Chief Financial officer (w.e.f. 18 December 2019)	
(m)	Priyadarshini Mahapatra	Company Secretary (w.e.f. 24 July 2019)	



### **B. OTHER RELATED PARTIES**

SI No	Name of the related party	Relationship	
(a)	Biocon Limited	Holding Company	
(b)	Biocon Sdn. Bhd., Malaysia	ellow subsidiary	
(c)	Biocon Pharma Limited	Fellow subsidiary	
(d)	Biocon Research Limited	Fellow subsidiary	
(e)	Biocon SA, Switzerland	Fellow subsidiary	
(f)	Biocon Biologics Limited, UK	Fellow subsidiary	
(g)	Biocon Pharma Inc, USA	Fellow subsidiary	
(h)	Biocon FZ LLC, UAE	Fellow subsidiary	
(i)	Biocon Biologics India Limited	Fellow subsidiary	
(j)	Biocon Healthcare Sdn. Bhd,	Fellow subsidiary	
	Malaysia		
(k)	Biocon Academy	Fellow subsidiary	
(1)	Bicara Therapeutics Inc	Fellow subsidiary	
(m)	Biocon Pharma UK Limited	Fellow subsidiary	
(n)	Biocon Pharma Ireland Limited	Fellow subsidiary	
(o)	Biocon Biosphere Limited	Fellow subsidiary	
(p)	Biocon Biologics Inc	Fellow subsidiary	
(q)	Biocon Foundation	Trust in which a director is a trustee	
(r)	Narayana Hrudayalaya Limited	Enterprise in which a director of the Company is a	
		member of board of directors	
(s)	Jeeves	Enterprise in which relative to a director of the	
		Company is proprietor	
(t)	Immuneel Therapeutics Private	Enterprise in which a director of the Company is a	
	Limited	member of board of directors	

### **II. TRANSACTIONS WITH RELATED PARTY**

(Amount in Indian Rupees Million)

Particulars	Transaction/ Balances	Half year ended 31 March 2020
Key management	Salary and perquisites	49
Personnel	[refer note (i) below]	
	Share based payments	61
	Sitting fees and commission	11
	Outstanding as at the year end	
	- Trade and other payables	5



Particulars	Transaction/ Balances	Half year ended
		31 March 2020
Holding company	Rent	34
	Power and facility charges	134
	[refer note (ii) below]	
	Other expenses reimbursed	55
	Purchase of assets	31
	Sale of services	42
	Outstanding as at the year end	
	- Trade and other payables	217
	- Rent deposits	23
	- Trade and other receivables	34
	Guarantee given to Central Excise Department	148
Fellow	Sale of services	214
subsidiaries	Rent and facility services	117
	Purchase of assets	56
	Purchase of goods	- *
	Outstanding as at the year end	
	- Trade and other payables	51
	- Trade and other receivables	328
Other related	Sale of services	-*
parties	Health services availed	2
	Contribution towards CSR	64
	Staff welfare expenses	2
	Investment in compulsorily convertible debentures	100

<sup>\*</sup> Less than Rs. 0.5 million.

#### **Notes:**

- (i) The remuneration to the key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are determined on an actuarial basis for the Company as a whole.
- (ii) The Company has entered into an arrangement for lease of land on lease basis and a service agreement with 'Biocon SEZ Developer' of Biocon Limited for availing certain facilities and services. The facility charges of Rs. 51 million and power charges (including other charges) of Rs. 83 million have been charged by Biocon Limited for the half year ended 31 March 2020.
- (iii) The above disclosures include related parties as per IND-As 24 on "Related Party Disclosures" and Companies Act, 2013.
- (iv) All transactions with these related parties are priced on an arm's length basis and none of the balances are secured.